Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study-Reference-Cited by-同舟云学术

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Published:2014 Issue:5 Volume:5 Page:320-327
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Gamucci Teresa,Michelotti Andrea,Pizzuti Laura,Mentuccia Lucia,Landucci Elisabetta,Sperduti Isabella,Di Lauro Luigi,Fabi Alessandra,Tonini Giuseppe,Sini Valentina,Salesi Nello,Ferrarini Ilaria,Vaccaro Angela,Pavese Ida,Veltri Enzo,Moscetti Luca,Marchetti Paolo,Vici Patrizia

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal;PharmacoEconomics - Open;2023-04-21

2. Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies;Targeted Oncology;2022-11

3. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study;Breast Cancer Research;2022-10-28

4. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting;Chemotherapy;2022-09-15

5. Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer;Breast Cancer Research and Treatment;2021-11-29